Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children’s Oncology Group study AALL0232
Michael J. Borowitz(Johns Hopkins University), Eric Larsen(New England Cancer Specialists), Mignon L. Loh(Seattle Children's Hospital), Brent L. Wood(University of Southern California), Stephen P. Hunger(Children's Hospital of Philadelphia), Elizabeth A. Raetz(NYU Langone Health), Yunfeng Dai(University of Florida), Naomi Winick(The University of Texas Southwestern Medical Center), Cheryl L. Willman(Mayo Clinic), Andrew J. Carroll(University of Alabama at Birmingham), William L. Carroll(NYU Langone Health), Meenakshi Devidas(National Institutes of Health), Nyla A. Heerema(The Ohio State University), Wanda L. Salzer(Maine Medical Center), James B. Nachman(University of Chicago), Julie M. Gastier‐Foster(Nationwide Children's Hospital)
Cited by 356
Related Papers
Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring
|Science|1999|11.6k
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
|Blood|2009|4.4k
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
|Journal of Clinical Oncology|2003|2.7k